IL1A and COVID-19: These finding highlight the concept of targeting macrophage in COVID-19 as a current and future therapeutic strategy as it was reported that blocking macrophage pro-inflammatory molecules such as the treatment by IL-1α/β inhibitor anakinra provided encouraging perspectives (46).